Senhwa Biosciences, Inc., a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration has granted Fast Track Designation for Silmitasertib, a highly selective inhibitor of casein kinase 2 to treat patients with recurrent sonic hedgehog driven Medulloblastoma.
August 18, 2021
· 3 min read
